Bloomberg Businessweek
Bloomberg Businessweek
Bloomberg
Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People
8 minutes Posted Aug 21, 2024 at 11:57 am.
0:00
8:19
Download MP3
Show notes

Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg News Health Care Reporter Madison Muller discusses that patients taking Eli Lilly’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity.
Hosts: Tim Stenovec and Katie Greifeld. Producer: Paul Brennan. 

See omnystudio.com/listener for privacy information.